SCHEMBL26969090

SCHEMBL26969090

O=C(OCc1ccccc1)N1CCn2nc(CO)c(Br)c2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ PRMT1 Q99873 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ F2 P00734 1/20 0.41
▸ F12 P00748 1/20 0.41
▸ GRM5 P41594 5/20 0.41
▸ TMEM97 Q5BJF2 4/20 0.40
▸ SIGMAR1 Q99720 4/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ DHFR P00374 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ ADRA2B P18089 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ DRD1 P21728 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969129 0.83 MEN1 (0.44) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL29911282 0.81 L3MBTL1 (0.43) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL25408322 0.79 MEN1 (0.41) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL26969130 0.78 PRMT1 (0.47) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL16379679 0.78 MEN1 (0.48) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL24348526 0.77 GRM5 (0.43) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL16220593 0.76 SMN1; SMN2 (0.48) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL30609886 0.74 PTGDR2 (0.46) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL16220591 0.74 MEN1 (0.48) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL23778959 0.74 MEN1 (0.48) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416261-A1 ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES UNIV TEXAS (US) 2023-12-28 — — US disclosed
WO-2022192527-A1 ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416261-A1 ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES PRMT1, PRMT7, PRMT5 MEN1 688/4885KMT2A 81/4885NPSR1 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback